any industry organizations interested in participating in the selection of a pool of nonvoting industry representative candidates available to serve as temporary nonvoting members on its Risk Communication Advisory Committee (the Committee) for the Office of the Commissioner notify FDA in writing. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations for the pool will be accepted effective with this notice.

**DATES:** Any industry organization interested in participating in the selection of a pool of appropriate candidates for temporary nonvoting membership to represent industry interests must send a letter stating the interest to FDA by October 9, 2009, for vacancies listed in the notice. Concurrently, nomination material for prospective candidates should be sent to FDA by October 9, 2009.

ADDRESSES: All letters of interest and nominations should be submitted in writing to Lee L. Zwanziger (see FOR **FURTHER INFORMATION CONTACT).** 

FOR FURTHER INFORMATION CONTACT: Lee L. Zwanziger, Office of Policy, Planning and Budget, Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane, rm. 14-90, 301-827-2895, fax: 301–827–4050, RCAC@fda.hhs.gov. SUPPLEMENTARY INFORMATION: The agency requests nominations for a pool of nonvoting industry representative candidates for the Risk Communication Advisory Committee.

## I. The Risk Communication Advisory Committee

The Risk Communication Advisory Committee advises the Commissioner of Food and Drugs and designees on strategies and programs designed to communicate with the public about the risks and benefits of FDA-regulated products so as to facilitate optimal use of these products. The Committee also reviews and evaluates research relevant to such communication to the public by both FDA and other entities. The Committee also facilitates interactively sharing risk and benefit information with the public to enable people to make informed independent judgments about use of FDA-regulated products.

The FDA hopes to identify a pool of individuals who would have expertise in risk communication and would be identified with the interests of various segments of regulated industry. The Commissioner, or designee, shall have the authority to select one or more individuals to serve temporarily as nonvoting members; the number of

temporary members selected for a particular meeting will depend on the meeting topic(s).

## **II. Selection Procedure**

Any industry organization interested in participating in the selection of appropriate nonvoting member candidates to represent industry interests should send a letter stating that interest to the FDA contact (see ADDRESSES) within 30 days of publication of this document (see DATES). Within the subsequent 30 days, FDA will send a letter to each organization that has expressed an interest, attaching a complete list of all such organizations, and a list of all nominees along with their current resumes. The letter will also state that it is the responsibility of the interested organizations in each industry segment to confer with one another and to select one or two candidates (allowing for an alternate) from the segment for the pool within 60 days after the receipt of the FDA letter. For this purpose, "segments" should be understood in correspondence with the eight links listed on the FDA Web site: Food; drugs; medical devices; vaccines, blood and biologics; animal and veterinary; cosmetics; radiation-emitting products; and tobacco products (http:// www.fda.gov). The interested organizations are not bound by the list of nominees in selecting candidates. However, if no individuals are selected within 60 days, the Commissioner of Food and Drugs will select temporary nonvoting members as needed to represent industry interests.

# **III. Application Procedure**

Individuals may self-nominate and/or an organization may nominate one or more individuals to serve as a nonvoting industry representative. Within the 30 days, the following information should be sent to the FDA contact person: A current curriculum vitae of each nominee, current business and/or home address, telephone number, e-mail address, and the name of the committee of interest. FDA will forward all nominations to the organizations expressing interest in participating in the selection process for the committee. (Persons who nominate themselves as nonvoting industry representatives will not participate in the selection process).

FDA has a special interest in ensuring that women, minority groups, individuals with physical disabilities and small businesses are adequately represented on its advisory committees, and therefore, encourages, nominations for appropriately qualified candidates from these groups.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: September 2, 2009.

#### David Horowitz,

Assistant Commissioner for Policy. [FR Doc. E9-21554 Filed 9-8-09; 8:45 am]

BILLING CODE 4160-01-S

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration** [Docket No. FDA-2009-N-0410]

**Request for Notification from Industry** Organizations Interested in **Participating in the Selection Process** for Nonvoting Industry Representatives on Medical Device **Advisory Committee Panels and Request for Nonvoting Industry Representatives on Medical Device Advisory Committee Panels** 

**AGENCY:** Food and Drug Administration,

HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting that any industry organization interested in participating in the selection of nonvoting industry representatives to serve on certain device panels of the Medical Devices Advisory Committee in the Center for Devices and Radiological Health notify FDA in writing. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for current vacancies effective with this notice.

**DATES:** Any industry organizations interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating that interest to FDA by October 9, 2009, for the vacancies listed in this notice. Concurrently, nomination materials for prospective candidates should be sent to FDA by October 9, 2009.

ADDRESSES: Send all letters of interest and nominations to Kathleen L. Walker (see FOR FURTHER INFORMATION CONTACT).

## FOR FURTHER INFORMATION CONTACT:

Kathleen L. Walker, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 5238, Silver Spring, MD 20993, 301-796-5964, e-mail: kathleen.walker@fda.hhs.gov.

**SUPPLEMENTARY INFORMATION: Section** 520(f)(3) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(f)(3)), as amended by the Medical Device Amendments of 1976, provides that each medical device panel include one nonvoting member to represent the

interests of the medical device manufacturing industry.

FDA is requesting nominations for nonvoting members representing industry interests for the following vacancies listed in table 1 of this document.

TABLE 1.

Medical Devices Panels	Approximate Date Needed
Dental Products Panel	November 1, 2009
General Hospital and Personal Use Devices Panel	January 1, 2010
Hematology and Pathology Devices Panel	March 1, 2010
Immunology Devices Panel	March 1, 2010
Ophthalmic Devices Panel	November 1, 2009

## I. Functions

The functions of the medical device panels are listed as follows: (1) Review and evaluate data on the safety and effectiveness of marketed and investigational devices and make recommendations for their regulation, (2) advise the Commissioner of Food and Drugs regarding recommended classification or reclassification of these devices into one of three regulatory categories, (3) advise on any possible risks to health associated with the use of devices, (4) advise on formulation of product development protocols, (5) review premarket approval applications for medical devices, (6) review guidelines and guidance documents, (7) recommend exemption to certain devices from the application of portions of the act, (8) advise on the necessity to ban a device, (9) respond to requests from the agency to review and make recommendations on specific issues or problems concerning the safety and effectiveness of devices, and (10) make recommendations on the quality in the design of clinical studies regarding the safety and effectiveness of marketed and investigational devices.

#### II. Selection Procedure

Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests should send a letter stating that interest to the contact person (see FOR FURTHER INFORMATION CONTACT) within 30 days of publication of this notice. Within the subsequent 30 days, FDA will send a letter to each organization that has expressed an interest, attaching a complete list of all such organizations, and a list of all nominees along with their current resumes. The letter will also state that it is the responsibility of the interested organizations to confer

with one another and to select a candidate, within 60 days after the receipt of the FDA letter, to serve as the nonvoting member to represent industry interests for a particular device panel. The interested organizations are not bound by the list of nominees in selecting a candidate. However, if no individual is selected within the 60 days, the Commissioner of Food and Drugs will select the nonvoting member to represent industry interests.

## III. Qualifications

Persons nominated for the device panels should be full time employees of firms that manufacture products that would come before the panel, or consulting firms that represent manufacturers, or have similar appropriate ties to industry.

## **IV. Application Procedure**

Individuals may self-nominate and/or an organization may nominate one or more individuals to serve as a nonvoting industry representative. Within the 30 days, the following information should be sent to the FDA contact person (see FOR FURTHER INFORMATION CONTACT): A current curriculum vitae of each nominee, current business and/or home address, telephone number, e-mail address, and the name of the device panel of interest. FDA will forward all nominations to the organizations expressing interest in participating in the selection process for the device panel. (Persons who nominate themselves as nonvoting industry representatives will not participate in the selection process).

FDA has a special interest in ensuring that women, minority groups, individuals with physical disabilities, and small businesses are adequately represented on its advisory committees, and therefore, encourages nominations

for appropriately qualified candidates from these groups.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: September 2, 2009.

#### David Horowitz,

Assistant Commissioner for Policy.
[FR Doc. E9–21555 Filed 9–8–09; 8:45 am]
BILLING CODE 4160–01–8

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration [Docket No. FDA-2009-N-0412]

Request for Nominations for Voting and Nonvoting Consumer Representative Members on Public Advisory Committees and Panels

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for voting and nonvoting consumer representatives to serve on the National Mammography Quality Assurance Advisory Committee (NMQAAC) and certain devices panels of the Medical Devices Advisory Committee in the Center for Devices and Radiological Health (CDRH).

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, encourages nominations of qualified candidates from these groups.

**DATES:** Nominations will be accepted for current vacancies and for those that will or may occur through October 31, 2010. Because vacancies occur on various